2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - Great Hall BC
Technology and Procedures, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Adult, Pediatric
PAPER

384 Integrated transcriptomic and proteomic profiling identifies AML restricted immunotherapy targets

Benjamin J. Huang, MD, Jenny Smith2, Rhonda E. Ries, MA3, Jack H. Peplinski, MSc4, Maria Pardo5, Yi Hsiao, PhD6, Marina A. Gritsenko7, Rosalie Chu8, Nicholas J. Day, PhD9, Chad A. Hudson, MD, Ph.D10, Pranav Gona11, Colin Smith12, Liana Abdullah13, Derek Stirewalt, MD14, Alessandro Baldi, PhD15, Torsten Haferlach, MD, PhD16, Danielle Kirkey17, Katherine Tarlock I, MD18, Andrew J. Menssen, Ph.D., HCLD(ABB)19, Michael Loken, PhD20, Jasmin Bavarva, PhD21, Xu Zhang, PhD22, Tao Liu23, Marcin P. Cieslik, PhD24, Alexey Nesvizhskii, PhD25, Scott N Furlan, MD26, Xiaotu Ma, PhD27, Franco Locatelli, MD PhD28, Soheil Meshinchi, MD, PhD29
1 University of California, San Francisco, San Francisco, California, United States
2 Bambino Gesù Children's Hospital, Rome, Italy
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Hematologics, Seattle, Washington, United States
6 University of Michigan, Ann Arbor, Michigan, United States
7 Pacific Northwest National Laboratory, Richland, Washington, United States
8 Pacific Northwest National Laboratory, Richland, Washington, United States
9 Pacific Northwest National Laboratory, Richland, Washington, United States
10 Hematologics, Seattle, Washington, United States
11 University of California, San Francisco, San Francisco, California, United States
12 University of California, San Francisco, San Francisco, California, United States
13 University of California, San Francisco, San Francisco, California, United States
14 Fred Hutchinson Cancer Center, Seattle, Washington, United States
15 MLL Munich Leukemia Laboratory, Munich, Germany
16 MLL Munich Leukemia Laboratory, Munich, Germany
17 Fred Hutchinson Cancer Center, Seattle, Washington, United States
18 Seattle Children’s Hospital, Seattle, Washington, United States
19 Hematologics, Seattle, Washington, United States
20 Hematologics, Seattle, Washington, United States
21 National Cancer Institute, Rockville, Maryland, United States
22 National Cancer Institute, Rockville, Maryland, United States
23 Pacific Northwest National Laboratory, Richland, Washington, United States
24 University of Michigan, Ann Arbor, Michigan, United States
25 University of Michigan, Ann Arbor, Michigan, United States
26 Fred Hutchinson Cancer Center, Seattle, Washington, United States
27 St Jude Children's Research Hospital, Memphis, Tennessee, United States
28 Bambino Gesù Children's Hospital, Rome, Italy
29 Fred Hutchinson Cancer Center, Seattle, Washington, United States

Immunotherapies are transforming the therapeutic landscape for many cancers, but to date, immunotherapeutic approaches to target acute myeloid leukemia (AML) have been associated with disappointing response rates. Pediatric AML is molecularly distinct from AML diagnosed in older adult patients, suggesting that distinct immunotherapy approaches may be need for each. Here, we generated large-scale transcriptome and proteome datasets to identify novel candidate immunotherapy targets expressed on pediatric AML cells, but not on normal hematopoietic cells. We used bulk transcriptomes from 2,052 unique pediatric AML patients to nominate targets, assessed their expression at single cell resolution, and used proteomic techniques (mass spectrometry and flow cytometry) to validate that their expression is restricted to AML cells (rather than normal hematopoietic cells) and that they are expressed at the cell surface, respectively.

Clinical and biological data were combined from patients enrolled on two consecutive COG phase 3 trials for de novo AML: AAML0531 (NCT00372593) and AAML1031 (NCT01371981). Each protocol was approved by the National Cancer Institute (NCI) central institutional review board (IRB) and the local IRB for each participating institution. Patients and/or families provided informed consent or assent as appropriate. Bulk transcriptome sequencing (RNA-seq) was performed on diagnostic samples from 2,052 patients, paired relapsed samples from 410 patients, 68 normal bone marrow (NBM) controls, and 16 normal CD34 sorted peripheral blood mononuclear cell (CD34+ PBMC) controls. Single cell RNA and ATAC sequencing (scRNA/ATAC-seq) was performed on diagnosis, remission, and relapse samples obtained from 28 patients, as previously described (Lambo, et al. Cancer Cell. 2023), and non-malignant single cells were used as controls. Mass spectrometry based proteomics and flow cytometry were performed on diagnostic samples from 85 and 788 patients, respectively (each with 10 NBM controls). Flow cytometry was specifically used to evaluate the cell surface expression for 12 candidate immunotherapy targets identified based on our transcriptomic-proteomic profiling.

Bulk transcriptome sequencing (N = 2,052) uncovered 982 candidate targets that are expressed in AML (or a genetic subtype of AML) and lowly expressed in NBM and CD34+ PBMCs. Among these, 176 candidate targets are expressed at the cell surface. We identified targets that are actively undergoing preclinical or clinical development, such as CD70, MSLN, CD265, PRAME, CLEC2A, and FOLR1. We also uncovered novel targets that have not yet been evaluated in AML from an immunotherapy standpoint, such as CSPG4, LAMP5, and CD56. Importantly, our candidate targets are differentially overexpressed compared to normal hematopoietic cells (AML versus NBM and CD34+ PBMCs) and to a greater extent than either CD33 or CD123.

Single cell profiling (N = 28) uncovered differential leukemia stem cell (LSC) versus hematopoietic stem cell (HSC) expression patterns and allowed for direct comparisons between diagnosis and relapse (since analysis of bulk RNA-seq at relapse is often limited by low tumor burden). Since scRNA/ATAC-seq depth is shallow compared to bulk RNA-seq, we focused our analysis on targets with gene expression that is sufficiently high to allow for evaluation with this approach.

Mass spectrometry based proteomics (N = 85) and flow cytometry (N = 788) were used to evaluate for the protein abundance and cell surface expression of candidate targets, respectively. Flow cytometry focused on 12 candidate targets that had been identified based on our transcriptomic-proteomic profiling. NBM controls were included for both proteomics and flow cytometry, which allowed us to assess for differential protein expression (AML versus NBM). Proteomic evaluation of CD123 uncovered genetic subtype specific differences in CD123 protein expression, suggesting that low response rates observed in clinical trials targeting CD123 could be due (in part) to the absence of genetics-based eligibility criteria.

Our study uncovers the largest number of novel and promising immunotherapy targets for pediatric AML at a time when CD33 and CD123 targeting has failed and new approaches are needed. Our discovery platform has helped uncover and advance three AML-restricted targets (FOLR1, CLEC2A and MSLN) that are currently undergoing clinical trial evaluation for AML in the United States and Italy.

Benjamin J. Huang, MD: No relevant conflicts of interest to declare.